Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Melanoma treatment details. Chemotherapy. Immunotherapy. University of Schleswig-Holstein, Kiel, Germany

Survival: 12.2 months
Toxicity Grade: 4
Treatments: Chemotherapy
Country: Germany
City/State/Province: Kiel
Hospital: University of Schleswig-Holstein
Journal: Link
Date: 7/2008

Patients: This phase II study involved 28 patients with metastatic melanoma. There were 16 men and 12 women. The median age was 56, ranging from 42 to 69 years old.

Treatment: Patients were treated with the chemotherapy drug dacarbazine and the immunotherapy interferon-alpha-2a (IFN).

Toxicity: Grade 4 leucopenia was reported in one patient, this got better after the IFN treatment stopped. Grade 3 toxicities included leucopenia/neutropenia, headache, dizziness, fatigue, thrombocytopenia, and high levels of liver enzymes.

Results: The median overall survival was 12.25 months (403 days).

Support: This study was supported by research funds from Roche Pharma AG, which markets IFN as Pegasys.

Correspondence: Dr. Axel Hauschild

E-mail to a Friend Email Physician More Information